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Abstract 
The article briefly presents currently accessible dry powder inhalers (DPI). Basing on the data from the literature, we discussed the 
most common mistakes related to the utilisation of DPI as well as their clinical and economic consequences. We also extensively 
analysed all factors that may influence the efficacy and safety of inhaler therapy of asthma and COPD, mostly with the use of 
DPI. In addition, we indicated the potential to improve the efficacy of inhaler therapy from the doctor and COPD or asthma patient 
perspective. We also presented a DPI choice algorithm including the patient’s preferences and competences. 
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Introduction
The article aims to discuss the factors which 
influence the correct use of a dry powder inhaler 
(DPI). A special emphasis has been put on the 
elements depending on the doctor and on the 
patient. We made a survey of the most important 
publications from the last 15 years, accessible 
in the PubMed database, which concern the 
technique of inhalation with DPI, errors made 
by patients with asthma or chronic obstructive 
pulmonary disease who use that type of inhalers 
as well as the rules of a right DPI choice.
Dry powder inhalers — today and yesterday
Medical aerosols are biphasic dispersed 
preparations. In case when a colloid is formed 
by liquid droplets dispersed in gas medium, it 
is called a liquid aerosol. If the dispersed phase 
is set up with solid particles, it is called a solid 
(powder) aerosol [1]. The dry powder aerosols are 
produced by dispersion in the air of the previous-
ly appropriately developed (micronised and mea-
sured out) dose of the powdered drug. That is why 
these devices are called dry powder inhalers [2] 
and are the most numerous and highly technically 
diversified (construction and mechanism of ac-
tion) group of inhaler devices [3, 4]. The Figure 1 
presents the categories of DPI based on the type 
of the aerosolization of the powder and on the 
preparation of the drug dose. The examples of DPI 
present on the Polish market are also included. 
In the passive DPI patients inspiration is 
used to disaggregate the powder molecules and to 
change them into aerosol. The acceleration during 
the initial phase of the inspiration, the amount 
of the peak inspiratory flow (PIF), time to reach 
a PIF, the respiratory capacity and the duration 
of the expiration are crucial for the process [5, 
6]. The necessity to take an appropriately forced, 
deep and long inspiration limits the accessibility 
of these type of DPI to patients incapable of per-
forming this inspiratory manoeuvre [4]. As a rule, 
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Dry powder inhalers
The aerolisation affected by inspiratory 
ow generated by the patient 
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The aerolisation not -affected by patient 
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with reservoir
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® ®
Disc , Orbicel , 
® ®
Ellipta , Forspiro  
® ®
Turbuhaler , Easyhaler , 
® ®
Novolizer , Twisthaler , 
® ®
Genuair , Nexthaler
®
Spiromax
Figure 1. Types of dry powder inhalers
these are elderly people with muscles weakened 
by the chronic disease process, persons with 
psychiatric and /or neurologic disorders as well 
as children under 6 years of age . In these groups 
of patients, there is a high risk of not generating 
the optimal inspiratory flow. And only the opti-
mal inspiratory flow guarantees the appropriate 
process of disaggregation and aerosolisation of the 
powder, an optimal penetration and deposition 
of such an aerosol in the respiratory tract and, as 
a result, a clinically effective inhalation [7–13]. 
In the active DPI, the processes of disaggre-
gation and aerosolisation are independent from 
patients’ inspiration, which makes this type 
of inhalers easier to use and assures a highly 
predictable characteristic of the aerosol cloud. 
A good and, up to the present, the only example 
of this type of inhaler is Airmax®/Spiromax® [14]. 
In the past few years some new passive DPI have 
entered the market (in order of appearing in the 
market): NEXThaler®, Ellipta®, Forspiro® or Zon-
da® [15–18]. The new devices usually generate 
aerosols which have better parameters, normally 
practically independent from the patient’s inspi-
ratory flow but concurrently more patient-friendly 
in the everyday use compared with the previ-
ously appllied devices [19–21]. Ellipta® is a good 
example of such an inhaler. The implement has 
replaced a popular for many years Discus® [22]. 
The construction (blisters inhaler) and the use 
of this new inhaler (only 3 simple steps) has de-
creased the risk of inhalation errors, compared 
with the older types of DPI [21]. The Forspiro® 
inhaler has similar features, however, it demands 
5–6 consecutive actions [17, 23].
How much do the errors in inhalation  
from DPI cost?
 Only the infallibly performed drug inhala-
tion is clinically effective and safe for the patient. 
The inhalation errors may be divided into simple 
and critical. The first ones may decrease the clini-
cal efficacy of a given inhaler, and the second ones 
make the inhalation practically totally clinically 
ineffective [24]. The DPI inhalation errors are 
mostly specific to a given type of inhaler but there 
are also some errors (non-specific), common to all 
DPI [25]. The most frequent non-specific errors 
include as follows: not taking a maximally deep 
expiration (to the level of the functional residual 
capacity [FRC]) before inhalation, incorrect body 
position during the inhalation, too slow or too 
shallow inspiration via the inhaler as well as not 
holding the breath after the inhalation [26]. The 
list of the specific errors is much more longer and 
depends on the type of DPI [25]. 
The results of the study by Sanchis et al. [27] 
based on the systemic overview of the 144 pub-
lications from the years 1965–2014 have shown 
that over the last 50 years the percentage of pa-
tients committing mistakes during the inhalation 
remains stable , i.e. it oscillates between 45 and 
17% [27]. The mistakes in the inhalation therapy 
concern all types of inhalers (the pressurised me-
tered dose inhalers, DPI, metered dose inhalers 
(MDI) of a liquid drug, nebulisers), and the per-
centage of patients depends on the analysed pop-
ulation (patients age, type of the disease, country), 
type of the inhaler and patients education level. 
For example, the results of the study by Molimard 
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et al. [28] from the year 2003 showed that at 
least one mistake had been made by 49–54% of 
patients treated in a standard outpatient clinic/in 
a medical practice by a general practitioner. More-
over, at least one critical mistake had been made 
by 11% (Dysk®) to 32% (Turbuhaler®) of treated 
patients. A systemic review with meta-analysis 
of the errors made by patients with asthma and 
COPD in several European countries has been 
recently published [29]. The authors of the review 
have proved that the critical mistakes were made 
during the inhalation, depending on the used DPI, 
by 14.2–42.2% of patients (on average in 28.4%). 
The data are shown in Table 1. 
The mistakes made by patients with asthma 
or COPD during the inhalation influence the 
constitution of the aerosol cloud and the depo-
sition of the rug molecules what has a negative 
impact on the therapeutic efficacy of the inhaled 
drugs [30,31]. For example, too weak inspiration 
(a suboptimal inspirational flow), which is one 
of the most frequent errors during the inhalation 
from the DPI, increases significantly the risk of 
uncontrolled asthma (OR [odds ratio] =1.30, 95% 
CI 0.08–1.57 for Turbuhaler® and OR = 1.56, 95% 
CI 1.17–2.07 for Discus ®), as well as it increases 
the risk of asthma exacerbations [25]. In another 
paper, the authors evidenced that patients who 
obtained only a suboptimal value of the PIF (for 
a given DPI) had an higher risk of COPD exacerba-
tion, which demanded admission to the hospital 
[13]. Other critical mistakes in the inhalation 
technique with DPI increase almost twice the 
risk of admission to the emergency room due 
to a severe intensification of COPD (it concerns 
6.9% of patients making mistakes vs. 3.3% in the 
no mistake group [OR 1.86, 95% CI 1.14–3.04, 
p < 0.05]) [32]. 
Table 2.  Casual medical events induced by inappropriate tech-
nique of inhalation [modification according to 33] 
Casual medical events Increase of risk 
Admission to a hospital 47%
Visit to an emergency room 62%
Antibiotics therapy 50%
Oral glucocorticosteroids 54%
Medical leave 47%
The errors made during inhaler therapy should 
therefore increase the costs of therapy of asthma or 
COPD. Lewis et al. [33, 34] analysed the group of pa-
tients who were using inhaled glucocorticosteroids 
(GCS) and long-acting beta-2 agonists (LABA) with 
the popular DPI: Turbuhaler® (budesonide + formo-
terol) or with Accuhaler® (Disc) (fluticasone propio-
nate + salmeterol) for one year in several European 
countries. The study published in the year 2016 
supplied many practical conclusions [33]. Firstly, 
it was showed that the inappropriate technique of 
inhalation with the DPI significantly increases the 
risk of hospitalisation, visits to the emergency room, 
antibiotic therapy or the use of oral GCS (by 47%, 
62%, 50% and 54% respectively) (Table 2). 
Secondly, 5.4–20.7% of casual medical events 
and cost have been related to the incorrect tech-
nic of inhalation. Thirdly, additional direct costs 
increase the total therapy price per patient con-
tingent on incorrect inhalation technique to 271 
Euros per year in Spain, 466 Euros per year in 
Sweden and 506 Euros per year in the United 
Kingdom (data from 2014). Fourthly, the incor-
rect inhalation technique constituted 2.2-7.7% 
of direct expenses that generated an amount of 
782 million of Euros, considering the total cost of 
asthma/COPD management in these 3 countries 
which equalled 5.5 billion of Euros (data from 
2014). The similar data for Poland are missing 
but we should expect comparable proportions of 
costs. The same team of authors also proved that 
the change of the passive DPI to an active DP (easer 
inhalation for the patient) reduces the number of 
mistakes and improves the inhalation technique, 
which results in better control of the disease and 
generates substantial savings, mostly due to the 
reduction of the adverse medical events [34]. 
Factors influencing the efficacy  
and safety of inhaler therapy 
The scheme of factors which determine the 
efficacy and safety of inhaler therapy are shown 
Table 1.  The percentage of patients with at least one 
critical mistake made during the inhalation with 
the most commonly used dry powder inhalers 
(DPI) in Europe (modification according to [29])
Type of DPI 
(number of studies)
Percentage of patients  
and confidence interval
Aerolizer®
(n = 4) 14.2% [95% CI 11.0–18.1]
Discus®
(n = 9) 20.8% [95% CI 13.7–30.2]
Turbuhaler®
(n = 10) 40.1% [95% CI 28.6–52.9]
Handihaler®
(n = 3) 42.4% [95% CI 28.8–57.1]
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Figure 2. The elements which influence the correctness of the in-
halation technique of the patient and his compliance as well as the 
efficacy, safety and satisfaction of the patient from the recommended 
inhalation therapy
EducatorPhysician 
Inhaler Drug
Patient �  correctness of the 
inhaltion and compliance
Efcacy, safety, satisfaction 
from the therapy
Figure 3. Physician and patient-related factors which determine the correctness of inhalation and patients compliance and, as a result, efficacy, 
safety and patient’s satisfaction from the recommended inhalation therapy with a dry powder inhaler (DPI) 
in Figure 2. It is known since many years that it 
depends on the 5 following equally important 
factors: physician, drug, inhaler, educator and 
patient. These 5 elements are mutually related, 
which finally forms the correctness of the pa-
tient inhalation technique and his compliance. 
These two elements determine efficacy, safety 
and satisfaction of the patient from the recom-
mended inhalation therapy. The five factors are 
also influenced by the health care system in 
a given country, including such elements like: 
way of organisation of the health care system, 
rules and reimbursement rate of the inhalation 
drugs, access to specialists and health educators 
(in Poland usually a physician or a nurse are at 
the same time health educators) 
The most important physician and patient 
dependant elements related to the DPI are pre-
sented in Figure 3. 
How to improve the effectiveness of inhalation 
therapy — physician’s perspective 
A physician is a person that initiate the pri-
mary choice of the inhalation drug and then the 
selection of a particular inhaler containing a giv-
en drug or drugs. To choose a drug, the physician 
must apply his pathophysiologic knowledge, 
know the actual therapeutic recommendations in 
a given disease entity and the accessibility of the 
drugs on the local market (availability of a drug, 
its price and reimbursement level). This phase of 
selection of a drug is relatively easy. A choice of 
an inhaler containing a selected drug (drugs) is 
Physician Patient 
Choice of a drug and dose
Measurment of the peak 
inspiratory ow for a given DPI
Preferences while choosing 
the DPI
Choice of DPI
Education of the patient 
concerning the use of DPI
Compliance
During the next appointment 
check to see if the patient’s 
inhalation technique is correct
Ability to perform a correct inhalation 
from a given DPI (competences)
Knowledge of inhalation therapy 
(education level)
Preferences while choosing the DPI
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Table 3.  Dry powder inhalers (DPI) containing the inhalation drugs used to treat asthma and/or COPD registered  
in Poland (as of 01.09.2017, in the alphabetic order) 
Inhaler/Drug GCS in LABA GCS
in
+ LABA
SABA LAMA LAMA + 
LABA
1. Aerolizer®/Cyklohaler® + + – – – –
2. CNG-Breezhaler® – + – – + –
3. CNG-Fantasmino® + + – – – –
4. CNG – + – – – –
5. Dysk® + + + + – –
6. Easyhaler® + + + + – –
7. Ellipta® – – + – + +
8. Forspiro® – – + – – –
9. Genuair® – – – – + –
10. HandiHaler® – – – – + –
11. NEXThaler® – – + – – –
12. Orbicel® + – + – – –
13. Novolizer® + + – + – –
14. Turbuhaler® + + + – – –
15. Twisthaler® + – – – – –
16. Zonda® – – – – + –
CNG — a new generation cyclohaler; GCS in — inhalation glucocorticosteroids; LABA — long-acting beta-2 agonists; LAMA — long-acting muscarinic antagonists; 
SABA — short-acting beta-2 agonists; Orbicel® — a disc after many technical modernisations (a generic disc)
a next step. To make this choice, the physician 
must have knowledge concerning the aerosols and 
the market of inhalers, which changes dynamical-
ly in the recent years, also in Poland. This phase 
is much more difficult and the first errors may by 
committed, for example the physician may choose 
a DPI which is familiar to him without including 
the patient’s preferences [35].
In a case the patient is a child, selection of 
the inhaler is of crucial importance. In children 
under 5–6 years of age, nebulisers or drugs 
administered from meter dose inhalers (pMDI) 
combined with inhalation chamber are used [36]. 
Dry powder inhalers are devices of first choice in 
children older than 5–6 years of age and in adults, 
provided that they are capable of generating 
the PIF > 30 L/min using a particular DPI [37]. 
That is why, a consecutive step of selecting an 
optimal DPI is to test wether the patient can 
generate the optimal PIF. Some simple medical 
devices such as: In-Check DIAL, Turbutest, Tur-
buhaler — whistle or exercise-Disc may be helpful 
in the process. Some more technically advanced 
implements which may educate the patient and 
test the correctness of inhalation with the DPI are 
also accessible, for example: Vitalograph AIM or 
Inhalation [38, 39]. 
Then the physician should identify a patient 
with high risk of committing a mistake during 
the inhalation with a DPI. The following persons 
belong to a high risk group: patients over 60 years 
of age, with severe obstructive disturbances of 
the bronchi, with neurological disorders, lonely 
persons [26, 30]. These people need an appropri-
ate education and a DPI that requires as little as 
possible (which minimises the risk of committing 
an error). 
It is crucial to prescribe as little inhalers as 
possible. The optimal approach is to use differ-
ent drugs in one inhaler, for example from a DPI 
or a pMDI. This strategy decreases the risk of 
committing an error during the inhalation and 
may improve the control of asthma or COPD 
[40]. A broad range of accessible DPI may im-
pede the implementation of this rule. Poland 
is a  good example of the problem. Currently, 
16 different DPI are registered on the Polish 
market but only 8 of them contain 2 or more 
drugs used to treat asthma or COPD, and only 8 
of them contain a combination of two different 
drugs (Table 3) [17, 41]. 
The development of inhalers containing 
three different drugs may decrease the number 
of inhalers used by the patient. This strategy of 
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Table 4.  The number and description of steps necessary to perform a correct inhalation with a Ellipta®, Twisthaler®, 
NEXThaler®, Easyhaler®, Dysk® and Turbuhaler® inhaler (data from Summary of Product Characteristics and from 
the official patients’ instruction manuals of the inhalers) [46–51]
Inhaler Number  
of steps
Description and order of steps
Ellipta® 3 1. Slide a cover down, until you hear a ‘click’ 
2. Inhale the medicine 
3. Slide the cover up and cover a mouthpiece
Twisthaler® 3 1. Take off (turn off) the inhaler adapter
2. Inhale the medicine 
3. Put the adapter in place, screw it clockwise and press gently until you hear a ‘click’ 
NEXThaler® 3 1. Hold the NEXThaler firmly in the upright position and open the cover fully.
2. Inhale the medicine
3. Hold the NEXThaler once again firmly in the upright position and replace the cover over the mouthpiece
Disc® 4 1. Expose the mouthpiece. Hold the Discus horizontal in one hand. With your other hand, put your thumb on 
the small curved section. Slide it away from you. You should hear a click 
2. Push the lever to prepare the dose. Hold the inhaler flat and level with the mouthpiece facing you. Use your 
finger to slide the lever until you feel it click into place
3. Inhale the medicine
4. Close the inhaler: to close the inhaler put your thumb on the small curved section. Slide it to you. You 
should hear a click 
Turbuhaler® 4 1. Unscrew the cover and lift it off. You may hear a characteristic rattle sound
2. Load a dose by holding the inhaler upright. Turn the grip dial (coloured base portion) as far as it will go in 
one direction, then turn it back to the original position. The “click” you hear means that the inhaler is ready 
to use 
3. Inhale the medicine 
4.  Replace the cover and close it tightly 
Easyhaler® 5 1. Remove the mouthpiece cap
2.  Shake the device up and down 3–5 times, and then hold the device in an upright position
3. Place the inhaler between your index-finger and thumb, press the top of the device once. You will hear 
a click. Then release it until you hear another click 
4. Inhale the medicine 
5. Replace the mouthpiece cap
Every DPI has its specific characteristics which may influence patients’ preferences. For example, the Ellipta® inhaler is characterised by the following: ease of use 
(only 3 steps), simplicity of inhalation steps and the shape of the mouthpiece [52]
therapy with aerosols facilitates the education, 
decreases the risk of mistakes committed by 
patients and may be a more effective therapy 
than inhalation with 2–3 different DPI inhalers 
[42]. The most recent example of the three-drug 
therapy with a  single DPI is a combination of 
fluticasone furoate with umeclidinium bromide 
and with vilanterol in the Ellipta® inhaler [43].
The improvement of the efficacy of inhala-
tion therapy seen from the patient’s perspective 
requires as follows: to define the characteristics of 
inhaler important to a user, to choose a DPI con-
sistent with preferences and possibilities of the 
patient and to properly educate the patient. The 
experts suggest that the DPI constructors should 
really consider patients’ opinions and remarks 
[44]. This suggestion has been considered in the 
DPI recently introduced onto the market [15, 17]. 
From the patient point of view, a DPI should be 
maximally simple to use and should possess the 
following features: 
• As little steps to prepare an inhaler to use, as 
possible
• Construction that enables to change the order 
or to skip a step when using an inhaler 
• Easy and comfortable process of inhalation
• Possibility to test the correctness of the inha-
lation 
• Visualisation and/or acoustic information 
about the number of doses left in the inhaler 
 Modern DPI such as Ellipta®, NEXThaler®, 
or Twisthaler® have almost all listed above char-
acteristics (Table 4) [15, 45]. In case of older DPI 
(Dysk®, Turbuhaler®, Easyhaler®), the number of 
steps is higher and they are more complicated 
which, has been included in the patients’ instruc-
tion manuals. 
The patient should finally select the inhaler, 
however, quite often he is not a decision-maker. 
His preferences concerning the inhaler as well as 
some predispositions and skills to use the inhaler 
should be considered. This issue has been empha-
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sised since several years in the recommendations 
of The Aerosol Drug Management Improvement 
Team (ADMIT) [53–55] and in the most recent 
American advice [56].
How to choose a DPI?
The patient’s preferences should be always 
discussed and considered when choosing an 
inhaler. The scheme of choosing the DPI by 
a  physician, which has been proposed since 
several years by the experts, is shown in the 
Figure 4. 
Summary 
Dry powder inhalers have dominated the 
inhalation drugs market in many countries since 
several years. It is due to the numerous advantages 
of DPI and to the development of new, usually 
improved devices. A great diversity of DPI cause 
problems with selecting and using the inhalers 
by patients with asthma and COPD. The mista-
kes made during the utilisation of DPI result in 
many clinical consequences and cause important 
economic effects. The choice of an optimal DPI 
for a particular patient equally depends on com-
petences of the physician and on preferences and 
competences of the patient. These elements finally 
define the correctness of the patient’s inhalation 
technique and his compliance. They also determi-
ne the efficacy, safety and the patient’s satisfaction 
from the recommended inhalation therapy. 
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